Researchers use mathematical modeling and evolutionary principals to show importance of basing treatment decisions

April 30, 2018, H. Lee Moffitt Cancer Center & Research Institute
Credit: CC0 Public Domain

Cancer patients are commonly treated with the maximum dose they are able to withstand that does not cause too many toxic side effects. However, many patients become resistant to these treatments and develop cancer recurrence. Researchers at Moffitt Cancer Center are using mathematical modeling based on evolutionary principals to show that adaptive drug treatments based on tumor responses to prior treatment are more effective than maximum-tolerated dose approaches for certain tumor situations. Their new study discussing this approach was published in online ahead of print in Cancer Research.

Standard treatments and most clinical trials are based on the notion that physicians need to treat patients with the highest dose of a drug possible to kill the most cancer in the shortest amount of time. But often, cells manage to find ways to thrive by activating survival mechanisms.

"An evolutionary flaw in this maximum-tolerated dose strategy is the assumption that resistant populations are not present prior to therapy. It is now clear that can be insensitive even to that they have never seen before," explained study author Jill Gallaher, Ph.D., an applied research scientist in the Department of Integrated Mathematical Oncology at Moffitt.

According to the Moffitt team, this can be explained through the evolutionary principal of competitive release. An example of this can be found in the use of chemical pesticides for gardens and crops. When the highest pesticide dose is used, the insect population undergoes high selection pressure and those insects that are sensitive to the insecticide are killed. However, some insects are able to survive because of already existing resistance, and with the disappearance of their competitors, these insects are able to multiply and generate a resistant population. It has become clear that existing resistant tumor cells can respond the same way following treatment.

An alternative approach to using a maximum-tolerated dose for cancer treatment is to use an adaptive approach based on the tumor's response to the previous drug administration. The Moffitt researchers wanted to determine which treatment scenario, either a continuous maximum tolerated approach or an adaptive approach, was best suited for particular tumors. They performed their analysis by using mathematical modeling based on evolutionary principals and cell culture experiments. They simulated maximum dose strategies against adaptive strategies using different combinations of sensitive and resistant cell populations, and also took into consideration the ability of cells to migrate and different proliferation inheritance patterns.

The researchers discovered that in general, there is no single treatment approach that works best for all tumors, and that the ability of a tumor to respond to a particular treatment depends on the composition of the tumor. For example, they showed that tumors that are made up of cells that are similar to one another and sensitive to drug treatments tend to respond better to a continuous, approach. In a clinical setting, this approach may work best for tumors such as testicular cancer and certain lymphomas that tend to be more homogeneous. However, tumors that are made up of a mixture of sensitive and resistant cells tend to respond better to an adaptive treatment . Clinical examples of these types of tumors include melanoma, lung and breast cancer.

The researchers also analyzed different adaptive-treatment approaches. They compared a typical adaptive strategy with a treatment vacation strategy during which no treatment is given in between high doses. They reported that the high-dose fluctuations of treatment vacations work well to control tumor growth if the tumor is highly invasive or genetically changing.

The researchers hope that their work can convince others that patients may respond better to cancer treatments by using existing drugs in a smarter manner.

"Our work illustrates clearly the importance of using treatment response as a key driver of treatment decisions, rather than fixed strategies. We strongly believe that the future of precision medicine should be focused not only on the development of new drugs but also in the smarter evolutionary use of preexisting drugs," said Alexander RA Anderson, Ph.D., chair of the Department of Integrated Mathematical Oncology at Moffitt.

Explore further: Mathematical modeling offers new way to understand variable responses to targeted therapy

More information: Jill A. Gallaher et al, Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies, Cancer Research (2018). DOI: 10.1158/0008-5472.CAN-17-2649

Related Stories

Mathematical modeling offers new way to understand variable responses to targeted therapy

April 3, 2018
Cancer therapies that target a specific protein have improved outcomes for patients. However, many patients eventually develop resistance to these targeted therapies and their cancer comes back. It is believed that differences ...

Using mathematical models to determine the best chemotherapy schedules

April 6, 2018
Can mathematical models predict how can cancer cells respond to varied chemotherapy schedules? In other words, should cancers associated with fast-growing tumors, like brain cancer, be treated using a low drug dose administered ...

Study shows low-dose chemo keeps cancer under control

February 24, 2016
Rather than try to wipe out cancer with powerful doses of chemotherapy, researchers said Wednesday an experimental approach using lower amounts of medication may work better to keep tumors under control.

Researchers use single-cell imaging and mathematical modeling to determine effective drug properties

March 13, 2018
Drug therapies that target a specific molecule have changed the way patients are treated for cancer and greatly improved survival rates. However, some patients do not respond to these therapies because the drug is not reaching ...

Researchers discover new approach to stimulate an immune response against tumor cells

January 30, 2018
New drugs that activate the immune system to target cancer cells have improved the lives of many patients with cancer. However, immunotherapies are not effective in all patients, and the success of these therapies depends ...

Team improves radiation therapy for head and neck patients

May 31, 2017
Radiation therapy is one of the most common treatments used to fight cancer, with an estimated 500,000 people each year receiving radiation therapy either alone or in combination with other treatments. Patients are often ...

Recommended for you

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.